Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

This study is testing a new drug called silevertinib combined with the standard chemotherapy drug temozolomide in patients with newly diagnosed glioblastoma (a serious brain cancer). The drug targets a protein called EGFR that is overactive in some brain tumors, and researchers hope that adding it to standard treatment will improve outcomes. **You may be eligible if...** - You have been newly diagnosed with glioblastoma (a specific aggressive type of brain tumor) - Your tumor shows certain genetic features, including EGFR alterations (and for the main part of the trial, specifically EGFRvIII and unmethylated MGMT) - You have completed surgery and standard radiation plus chemotherapy and your cancer has not yet progressed - It has been at least 4 weeks since your radiation therapy ended **You may NOT be eligible if...** - Your tumor has spread to multiple sites, outside the brain, or to the lining of the brain - Your tumor has progressed since starting treatment - You only had a biopsy (without tumor removal surgery) - You have received prior treatment targeting EGFR or with bevacizumab, immunotherapy, or certain implanted treatments - You plan to use Optune (a device-based therapy for brain cancer) Talk to your doctor to see if this trial is right for you.